HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maher, E. A. Articles by Todd, T. J. R. Search for Related Content PubMed PubMed Citation Articles by Maher, E. A. Articles by Todd, T. J. R.

J Thorac Cardiovasc Surg 1996;112:637-643
© 1996 Mosby, Inc.

GENERAL THORACIC SURGERY

PERICARDIAL SCLEROSIS AS THE PRIMARY MANAGEMENT OF MALIGNANT PERICARDIAL EFFUSION AND CARDIAC TAMPONADE

Received for publication Jan. 2, 1996 Revisions requested Feb. 16, 1996; revisions received March 13, 1996 Accepted for publication March 18, 1996. Address for reprints: Frances A. Shepherd, MD, FRCPC, The Toronto Hospital, ML2-035, 200 Elizabeth St., Toronto, Ontario, Canada M5G 2C4.

Abstract

Objective: The management of malignant pericardial effusion remains controversial. We present our experience with 93 patients referred for drainage and sclerosing procedures between 1979 and 1994.

Methods: With continuous electrocardiographic monitoring, a Kifa catheter was inserted percutaneously into the pericardial sac and allowed to drain. A 100 mg dose of lidocaine hydrochloride was instilled intrapericardially, followed by 500 to 1000 mg tetracycline or doxycycline hydrochloride in 20 to 50 ml normal saline solution. The catheter was clamped for 1 to 2 hours and then reopened, and the procedure was repeated daily until the net drainage was less than 25 ml in 24 hours.

Results: Subjects included 53 women and 40 men (median age 58 years). Eight patients could not undergo sclerosis because of technical failure. Eighty-five patients underwent sclerosis and required a median dose of 1500 mg of the sclerosing agent (range 500 to 700 mg), given in a median of three injections (range one to eight). Complications included pain (17 patients), atrial arrhythmias (eight patients), fever with temperature greater than 38.5° C (seven patients), and infection (one patient). Two patients had cardiac arrest before sclerosis could be attempted. Sixty-eight patients (73%) had the effusion controlled for longer than 30 days, for an overall control rate of 81%. Seven other patients had control of the effusion but died of progressive malignant disease in less than 30 days. The overall median survival was 98 days (range 1 to 1724 days). Comparison of these results with outcomes reported for patients with malignant pericardial effusion who underwent surgical drainage indicates that drainage and sclerosis provide similar survivals but sclerosis carries lower morbidity, mortality, and recurrence rates.

Conclusion: Percutaneous drainage and sclerosis constitutes a safe and effective treatment for malignant pericardial effusion. Surgical management should be reserved for the small percentage of cases that cannot be controlled by this method. (J THORACCARDIOVASCSURG1996;112:637-43)

This article has been cited by other articles:

				S. G. Tejwani, S. B. Cohen, and J. P. Bradley Management of Morel-Lavallee Lesion of the Knee: Twenty-Seven Cases in the National Football League Am. J. Sports Med., July 1, 2007; 35(7): 1162 - 1167. [Abstract] [Full Text] [PDF]

				R. M. Gowda, I. A. Khan, N. J. Mehta, M. R. Gowda, P. Hyde, B. C. Vasavada, and T. J. Sacchi Cardiac Tamponade and Superior Vena Cava Syndrome in Lung Cancer: A Case Report Angiology, November 1, 2004; 55(6): 691 - 695. [Abstract] [PDF]

				R. M. Gowda, I. A. Khan, N. J. Mehta, M. R. Gowda, P. Hyde, B. C. Vasavada, and T. J. Sacchi Cardiac Tamponade and Superior Vena Cava Syndrome in Lung Cancer: A Case Report Angiology, November 1, 2004; 55(6): 691 - 695. [Abstract] [PDF]

				A. Martinoni, C. M. Cipolla, D. Cardinale, M. Civelli, G. Lamantia, M. Colleoni, and C. Fiorentini Long-term Results of Intrapericardial Chemotherapeutic Treatment of Malignant Pericardial Effusions With Thiotepa Chest, November 1, 2004; 126(5): 1412 - 1416. [Abstract] [Full Text] [PDF]

				K. M. Frankel, F. W. Grannis Jr, C. A. Cullinane, and I. B. Paz Malignant Pericardial Effusions Chest, November 1, 2004; 126(5): 1713 - 1713. [Full Text] [PDF]

				K. Reynen, U. Kockeritz, and R. H. Strasser Metastases to the heart Ann. Onc., March 1, 2004; 15(3): 375 - 381. [Full Text] [PDF]

				K. M. Frankel Treating Malignancy-Related Effusions Chest, May 1, 2003; 123(5): 1775 - 1775. [Full Text] [PDF]

				B. Maisch, A.D. Ristic, S. Pankuweit, A. Neubauer, and R. Moll Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin Eur. Heart J., October 2, 2002; 23(20): 1625 - 1631. [Abstract] [Full Text] [PDF]

				T. S. M. Tsang, M. Enriquez-Sarano, W. K. Freeman, M. E. Barnes, L. J. Sinak, B. J. Gersh, K. R. Bailey, and J. B. Seward Consecutive 1127 Therapeutic Echocardiographically Guided Pericardiocenteses: Clinical Profile, Practice Patterns, and Outcomes Spanning 21 Years Mayo Clin. Proc., May 1, 2002; 77(5): 429 - 436. [Abstract] [PDF]

				C. Chiles, P. K. Woodard, F. R. Gutierrez, and K. M. Link Metastatic Involvement of the Heart and Pericardium: CT and MR Imaging RadioGraphics, March 1, 2001; 21(2): 439 - 449. [Abstract] [Full Text] [PDF]

				H. L. Porte, T. J. Janecki-Delebecq, L. Finzi, D. G. Metois, A. Millaire, and A. J. Wurtz Pericardoscopy for primary management of pericardial effusion in cancer patients Eur. J. Cardiothorac. Surg., September 1, 1999; 16(3): 287 - 291. [Abstract] [Full Text] [PDF]

				L. N. Girardi, R. J. Ginsberg, and M. E. Burt Pericardiocentesis and Intrapericardial Sclerosis: Effective Therapy for Malignant Pericardial Effusions Ann. Thorac. Surg., November 1, 1997; 64(5): 1422 - 1427. [Abstract] [Full Text]